Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Alkermes is a fully integrated biotechnology company focused on developing innovative treatments for unmet medical needs in various therapeutic areas. Their orexin program, specifically ALKS 7290 and ALKS 2680, shows promise in treating sleep disorders and could potentially lead to significant revenue growth. The company's commitment to exploring treatments for a range of conditions, including depression, schizophrenia, and cancer, demonstrates their dedication to improving patient quality of life and sets them apart in the biotechnology industry.

Bears say

Alkermes is a biopharmaceutical company with a negative outlook due to concerns about the commercial viability of its lead clinical candidate ALKS 2680, potential competition in the market for idiopathic hypersomnia treatments, and undervaluation of its orexin franchise. While ALKS 2680 could be a major opportunity for the company, there are concerns about its effectiveness and tolerability compared to current treatments. In addition, the potential for other companies to enter the market for idiopathic hypersomnia treatments could lead to increased competition and reduced market share for Alkermes. Furthermore, the company's orexin franchise, although potentially valuable, is not being appropriately valued in the market, and the base business is also undervalued.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.